Aggressive plasma-cell biology indicating need for intensified MM induction: plasma cell...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-MM-TRANSFORMATION-PROGRESSION`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-MM`
Sources	`SRC-ESMO-MM-2023` `SRC-NCCN-MM-2025`

Red Flag Origin

Definition	Aggressive plasma-cell biology indicating need for intensified MM induction: plasma cell leukemia (≥5% circulating plasma cells, or absolute count ≥500/µL), extramedullary disease at diagnosis (soft-tissue plasmacytoma not contiguous with bone), or rapid laboratory progression (≥25% rise in M-protein over 4-8 weeks pre-treatment).
Clinical direction	intensify
Category	transformation-progression
Shifts algorithm	ALGO-MM-1L

Trigger Logic

{
  "any_of": [
    {
      "finding": "plasma_cell_leukemia",
      "value": true
    },
    {
      "comparator": ">=",
      "finding": "circulating_plasma_cells_percent",
      "threshold": 5
    },
    {
      "finding": "extramedullary_disease_present",
      "value": true
    },
    {
      "finding": "m_protein_rise_25pct_in_4_8wk",
      "value": true
    }
  ],
  "type": "composite_score"
}

Notes

Plasma cell leukemia (PCL) — both primary and secondary forms have inferior PFS/OS on standard VRd; D-VRd or KCd is preferred. EMD at diagnosis (soft-tissue plasmacytoma not extending from bone): ≈30% worse PFS regardless of cytogenetics. ESMO MM 2023 §IV.2 explicitly recommends quadruplet (D-VRd / IsaVRd) for these high-risk presentations even in cytogenetically standard-risk patients. This RF intensifies toward D-VRd track, supplementing RF-MM-HIGH-RISK-CYTOGENETICS step 1.

Used By

Algorithms

ALGO-MM-1L - ALGO-MM-1L
ALGO-MM-2L - ALGO-MM-2L